Talk:Copanlisib
Add topic| This is the talk page for discussing improvements to the Copanlisib article. This is not a forum for general discussion of the subject of the article. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Copanlisib.
|
 | The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
 | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
Todos in the drug box
[edit]I had found two topics for clarification by appropriate and interested experts: a) the "| licence_US = " did not lead to the correct drugs@fda page, neither for Aliqopa, nor ALIQOPA nor copanlisib. b) the SMILES I copied from the old chembox. However, looking at the drugs chembl page, I found a differently looking SMILES entry.
Is this free-base vs. salt related? Which one to use?
As of 2019, Aliqopa is not APPROVED by FDA but it is CONDITIONALLY APPROVED
[edit]It has not yet demonstrated it's primary endpoint, but phase 2 analyses of efficacy endpoints were highly promising. The US FDA approval pipeline is starting to conditionally approve some drugs, with the condition being they have to go demonstrate the primary endpoints. This is subtle. But a conditionally approved drug may be removed from the market. — Preceding unsigned comment added by 76.191.127.162 (talk) 15:18, 7 October 2019 (UTC)
Unclear wording
[edit]"Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells."
This sounds either like Copansilib is an effective drug against cancerous B-cell or Copansilib is a dangerous drug that may actually help cancerous B-cell and lower the chance of survival. — Preceding unsigned comment added by Akangka (talk • contribs) 01:58, 6 January 2020 (UTC)
USPI wording: "Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines." 2003:E2:4F38:5B00:3DA4:12F9:6CF4:B62D (talk)